Measles: the United States, Mexico and Bolivia lose their measles elimination status
On 17 November 2026, the Pan American Health Organization (PAHO, the WHO regional office for the Americas) made an important announcement. Endemic measles transmission has returned in the United States, Mexico and Bolivia. As a result, all three countries lose their measles “elimination” status. For the United States, it is the first loss since the country reached elimination in 2000.
Background: what “elimination” means
A country has eliminated measles when the virus no longer circulates on its own within its borders. Imported cases and small outbreaks can still occur. However, chains of transmission die out quickly. Keeping this status requires very high population immunity. In fact, measles is one of the most contagious diseases known: one infected person can pass it on to as many as 18 unprotected people.
The Americas were the first region in the world to eliminate measles. However, the region lost its status in November 2025 because of sustained transmission in Canada. Canada has since interrupted the chain of transmission linked to that outbreak.
The news: the Commission’s decision
• The regional Commission that verifies measles and rubella elimination met from 10 to 13 November 2026
• The criterion: transmission becomes endemic again when the same genotype and lineage of the virus circulate without interruption for at least 12 months
• PAHO Director Jarbas Barbosa accepted the Commission’s recommendations for Bolivia, Mexico and the United States
• To regain the status, each country must submit a corrective action plan. In addition, it must show that transmission has stopped for at least 12 consecutive months
The figures
• From the start of 2026 to 13 November, the Americas confirmed 58,213 measles cases and 82 deaths
• In the same period of 2025 there were 12,806 cases, so cases have more than quadrupled
• The United States has reported over 5,400 cases in 2026, the highest number in decades
• In the United States, childhood coverage with the measles-mumps-rubella vaccine has fallen to around 92%. This is below the 95% threshold needed for herd immunity
The role of the laboratory
Above all, PAHO’s decision rests on laboratory work. To show that “the same virus” has circulated for more than a year, counting cases is not enough. Each case needs laboratory confirmation, and laboratories must then trace it back to its strain.
• Measles IgM antibodies in blood: they confirm a recent infection, usually a few days after the rash appears (see the page Measles antibodies)
• Detection of viral RNA by RT-PCR on a throat or nasopharyngeal swab and on urine: it allows early diagnosis, even in the first days of illness
• Genotyping of the virus found by PCR: it identifies the genotype and lineage, and therefore shows whether cases belong to the same transmission chain. In addition, it tells the vaccine strain apart from wild-type virus when a rash develops after vaccination, as PAHO itself recommends
• Measles IgG antibodies: they indicate protection from vaccination or past infection. For example, they can help healthcare workers or women planning a pregnancy, together with the rubella antibody test
What it means for us
The news concerns the Americas. However, measles travels with people, so every distant outbreak raises the risk of imported cases in Europe and Italy too. Measles is not a trivial illness. It can cause pneumonia, encephalitis, blindness and, in the most severe cases, death. In addition, it weakens the immune system for months after recovery.
If you are unsure whether you are protected, check your vaccination status with your family doctor. Your doctor will assess whether you need an antibody test or a vaccine dose according to the immunisation schedule (see the Vaccine dossier).
Who should take note
• Parents of young children, especially infants too young for the vaccine, who are protected only if the people around them are
• Adults who are not sure whether they have had measles or two doses of vaccine
• Healthcare workers and travellers to the Americas
• Women planning a pregnancy
Limitations
• The 2026 data are provisional, so they may change in the coming weeks
• National figures are averages: as PAHO stresses, they hide communities with much lower coverage, where the virus keeps circulating
• Case counts also depend on each country’s surveillance capacity, which varies from country to country
• Losing the status is a public health indicator. On its own, it does not describe the risk for an individual traveller
In summary
• The United States, Mexico and Bolivia have lost measles elimination status after more than 12 months of circulation of the same strain
• Cases in the Americas in 2026 are more than four times those of 2025, with 82 deaths
• Laboratory genotyping of the virus is the tool that documented continuous transmission
• According to PAHO, the way back to elimination is at least 95% coverage with two vaccine doses in every community
Sources:
PAHO, press release of 17 November 2026; Quotidiano Sanità; Reuters (via US News); Il Sole 24 Ore
Laboratory tests:
Anticorpi anti morbillo, Anticorpi anti rosolia (Rubeotest), Anticorpi anti parotite, Anticorpi anti varicella
Diseases, symptoms and related pages:
Morbillo, Dossier vaccini: obbligatori e facoltativi, Pediatria (malattie dei bambini), Polmonite bilaterale, Influenza 2026-2027: riparte RespiVirNet














































Discussion about this post